Article 22 entity architecture: two importers, one distributor and one lead establishment

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Article 22 turns exclusive agency from a default option into a matter that requires a specific exemption. Under that Article, the marketing rights holder must designate at least 2 EDE-licensed establishments as importers, designate one or more establishments as distributors, and designate 1 lead establishment among them to uniformly handle licensing affairs, vigilance and whole-lifecycle management. Each figure is a quantitative floor, and every designated establishment must actually import within the same calendar year. The Cabinet retains room to grant exemptions, but an exemption is the exception and cannot be treated as the premise of an architecture design. The old arrangement of handing registration, import and distribution to a single partner must be redrawn against this Article.

  • At least 2 importers and one or more distributors must be designated, with 1 lead establishment for licensing, vigilance and lifecycle management.
  • Every designated establishment must actually import within the calendar year; nominal designation is not enough.
  • Cabinet exemptions exist but are exceptional and cannot be assumed in advance.
  • Because the thresholds are minimums, adding a third importer is a resilience measure, not a violation.

2. Legal basis

The provisions below set the designation quotas, the annual actual-import duty and the exemption route, and connect them to the vigilance duties of the rights holder and the four eligible applicant categories.

RegulationReferencePublicationProvisionKey point
Federal Decree-Law on the Regulation of Medical Products, Pharmacists and Pharmaceutical EstablishmentsFederal Decree-Law No. 38/2024Issued 1 October 2024, effective 2 January 2025Article 22(1)(a)-(c)Designate at least 2 importers and one or more distributors, and designate 1 lead establishment for licensing affairs, vigilance and whole-lifecycle management
Federal Decree-Law on the Regulation of Medical Products, Pharmacists and Pharmaceutical EstablishmentsFederal Decree-Law No. 38/2024Issued 1 October 2024, effective 2 January 2025Article 22(2)-(4)Each designated establishment must actually import within the year; the Cabinet may decide on exemptions
Federal Decree-Law on the Regulation of Medical Products, Pharmacists and Pharmaceutical EstablishmentsFederal Decree-Law No. 38/2024Issued 1 October 2024, effective 2 January 2025Article 21(6)The rights holder must comply with EDE vigilance guidance; execution may be carried by the lead establishment
Federal Decree-Law on the Regulation of Medical Products, Pharmacists and Pharmaceutical EstablishmentsFederal Decree-Law No. 38/2024Issued 1 October 2024, effective 2 January 2025Article 6(1)(a)Four eligible applicant categories, independent of the import and distribution roles

3. Expert insights

Insight 1: the quantitative thresholds are minimum requirements, not a recommended configuration. The 2 importers and one or more distributors given in Article 22(1) are floors, and the law does not prohibit more. Our judgement is that for products with large import volumes and broad terminal coverage, going to 3 or more importers is the more resilient approach. The reason is that the same Article requires each designated establishment to import in fact during the year; once one establishment records zero imports for the year because of its own qualification or customs-clearance problems, the others cannot make up a structural gap, and the rights holder is directly exposed to compliance risk.

Insight 2: the lead establishment is a single point of administrative responsibility and carries more than mere coordination. Article 22 concentrates licensing affairs, vigilance and whole-lifecycle management in 1 lead establishment, closing the loop with Article 21(6), which requires compliance with EDE vigilance guidance. In our understanding, the lead establishment should be treated as the aggregation node of compliance responsibility: adverse event reporting, major variation applications under Article 15, and post-market reports under Article 23(3)-(4) should all have defined routing and record-keeping requirements written into the agreement, and cannot be left in boundary-less wording such as being responsible for related affairs.

Insight 3: the requirement that each establishment must actually import in the year is the dynamic obligation most easily missed. Article 22(2)-(4) points to actual import conduct rather than nominal designation, which means compliance status must be retrospectively verified on an annual cycle. A common mistake by Chinese manufacturers is to write the establishments into the submission once and then stop maintaining the arrangement; in the second year one designated establishment has no import record at all, and the paper architecture and the reality diverge. We recommend maintaining an annual import ledger, comparing customs declarations against arrival records establishment by establishment, and turning the question of whether imports actually occurred into an indicator that can be checked quarterly.

4. Practical recommendations

  • Redraw the entity relationship map: mark the specific roles, licence numbers and contact persons of importers, distributors and the lead establishment, avoiding role overlap.
  • Establish an annual import ledger recording customs declarations and arrival batches establishment by establishment, as evidentiary material for compliance with Article 22(2)-(4).
  • In the lead establishment agreement, write out item by item the time limits and record-keeping requirements for licensing affairs, vigilance reports, variation applications and post-market reports.
  • Set up backup arrangements for key importers, so that if one establishment cannot complete imports in a given year, the others can fill in within the same year.
  • Where exclusive arrangements are involved or configuration is objectively impossible, submit a written enquiry to EDE to confirm the Cabinet exemption position, and never substitute industry practice for an official reply.
  • Update all agency contracts comprehensively, deleting exclusive import or exclusive distribution clauses that conflict with the quantitative requirements of Article 22.

5. Verification checklist

  • □ At least 2 licensed importers have been designated for every marketed product, all licences within validity
  • □ One or more distributors have been designated, with importer and distributor roles not conflated
  • □ 1 lead establishment has been designated, and the agreement states the specific matters of licensing, vigilance and whole-lifecycle management
  • □ An annual import ledger has been established that can evidence the actual import records of each establishment for the year
  • □ All agency contracts have been cleared of exclusive clauses that conflict with Article 22
  • □ Any situation relying on a Cabinet exemption has obtained a written reply from EDE and is archived
  • □ The routing of vigilance reports and variation applications is defined in the agreements, with responsibility assigned to named persons

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team coordinates local authorised representative and importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail